The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Open accessAbstract
Biological molecules are increasingly becoming a part of the therapeutics portfolio that has been either recently approved for marketing or those that are in the pipeline of several biotech and pharmaceutical companies. This is largely based on their ability to be highly specific relative to small molecules. However, by virtue of being a large protein, and having a complex structure with structural variability arising from production using recombinant gene technology in cell lines, such therapeutics run the risk of being recognized as foreign by a host immune system. In the context of immune-mediated adverse effects that have been documented to biological drugs thus far, including infusion reactions, and the evolving therapeutic platforms in the pipeline that engineer different functional modules in a biotherapeutic, it is critical to understand the interplay of the adaptive and innate immune responses, the pathophysiology of immunogenicity to biological drugs in instances where there have been immune-mediated adverse clinical sequelae and address technical approaches for their laboratory evaluation. The current paradigm in immunogenicity evaluation has a tiered approach to the detection and characterization of anti-drug antibodies (ADAs) elicited in vivo to a biotherapeutic; alongside with the structural, biophysical, and molecular information of the therapeutic, these analytical assessments form the core of the immunogenicity risk assessment. However, many of the immune-mediated adverse effects attributed to ADAs require the formation of a drug/ADA immune complex (IC) intermediate that can have a variety of downstream effects. This review will focus on the activation of potential immunopathological pathways arising as a consequence of circulating as well as cell surface bound drug bearing ICs, risk factors that are intrinsic either to the therapeutic molecule or to the host that might predispose to IC-mediated effects, and review the recent literature on prevalence and intensity of established examples of type II and III hypersensitivity reactions that follow the administration of a biotherapeutic. Additionally, we propose methods for the study of immune parameters specific to the biology of ICs that could be of use in conjunction with the detection of ADAs in circulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
The who, how and where of antigen presentation to B cells
Batista, F. D., & Harwood, N. E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2454 · Cited by 775
Aalberse, R. C., van der Gaag, R., & van Leeuwen, J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.2.722 · Cited by 736
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Balázs, M., Martin, F., Zhou, T., & Kearney, J. F. (2002) · Immunity · doi:10.1016/s1074-7613(02)00389-8 · Cited by 624
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications
Smith, K. G. C., & Clatworthy, M. R. (2010) · Nature Reviews Immunology · doi:10.1038/nri2762 · Cited by 543
The role of chemokines in linking innate and adaptive immunity
Luster, A. D. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(01)00308-9 · Cited by 474
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14541-2 · Cited by 383
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
T-cell regulation: with complements from innate immunity
Kemper, C., & Atkinson, J. P. (2007) · Nature Reviews Immunology · doi:10.1038/nri1994 · Cited by 340
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Koren, E., Smith, H. W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y.-C., Devanarayan, V., Gorovits, B., Gupta, S., et al. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.001 · Cited by 328
Mouse and human neutrophils induce anaphylaxis
Jönsson, F., Mancardi, D. A., Kita, Y., Karasuyama, H., Iannascoli, B., Van Rooijen, N., Shimizu, T., Daëron, M., & Bruhns, P. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45232 · Cited by 306
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Bindon, C. I., Hale, G., Brüggemann, M., & Waldmann, H. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.1.127 · Cited by 292
Adverse side‐effects to biological agents
Pichler, W. J. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01058.x · Cited by 283
Ponce, R., Abad, L., Amaravadi, L., Gelzleichter, T., Gore, E., Green, J., Gupta, S., Herzyk, D., Hurst, C., Ivens, I. A., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.03.012 · Cited by 270
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Hershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., & Sundy, J. S. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4500 · Cited by 266
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02280.x · Cited by 238
Role of Aggregated Human Growth Hormone (hGH) in Development of Antibodies to hGH*
MOORE, W. V., & LEPPERT, P. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-4-691 · Cited by 220
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
Jani, M., Barton, A., Warren, R. B., Griffiths, C. E. M., & Chinoy, H. (2014) · Rheumatology · doi:10.1093/rheumatology/ket260 · Cited by 217
Mechanisms of Immune Complex–Mediated Neutrophil Recruitment and Tissue Injury
Mayadas, T. N., Tsokos, G. C., & Tsuboi, N. (2009) · Circulation · doi:10.1161/circulationaha.108.771170 · Cited by 208
Bergseth, G., Ludviksen, J. K., Kirschfink, M., Giclas, P. C., Nilsson, B., & Mollnes, T. E. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.05.221 · Cited by 203
van Schouwenburg, P. A., van de Stadt, L. A., de Jong, R. N., van Buren, E. E. L., Kruithof, S., de Groot, E., Hart, M., van Ham, S. M., Rispens, T., Aarden, L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201445 · Cited by 203
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
Anderson, P. J. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.005 · Cited by 202
Fc receptors are major mediators of antibody based inflammation in autoimmunity
Hogarth, P. M. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00409-0 · Cited by 189
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
van der Laken, C. J., Voskuyl, A. E., Roos, J. C., Stigter van Walsum, M., de Groot, E. R., Wolbink, G., Dijkmans, B. A. C., & Aarden, L. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057406 · Cited by 184
Factor IX Inhibitors and Anaphylaxis in Hemophilia B
Warrier, I., Ewenstein, B. M., Koerper, M. A., Shapiro, A., Key, N., DiMichele, D., Miller, R. T., Pasi, J., Rivard, G. E., Sommer, S. S., et al. (1997) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199701000-00003 · Cited by 183
The complement system in B cell regulation
CARROLL, M. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.03.017 · Cited by 177
Aarden, L., Ruuls, S. R., & Wolbink, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.011 · Cited by 175
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
Sethu, S., Govindappa, K., Alhaidari, M., Pirmohamed, M., Park, K., & Sathish, J. G. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0189-7 · Cited by 168
van Schouwenburg, P. A., Bartelds, G. M., Hart, M. H., Aarden, L., Wolbink, G. J., & Wouters, D. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.09.005 · Cited by 163
Differential effect of drug interference in immunogenicity assays
Hart, M. H., de Vrieze, H., Wouters, D., Wolbink, G.-J., Killestein, J., de Groot, E. R., Aarden, L. A., & Rispens, T. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.019 · Cited by 160
Bourdage, J. S., Cook, C. A., Farrington, D. L., Chain, J. S., & Konrad, R. J. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.07.004 · Cited by 157
Maneiro, J. R., Salgado, E., & Gómez-Reino, J. J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7430 · Cited by 152
Human FcγRIIA induces anaphylactic and allergic reactions
Jönsson, F., Mancardi, D. A., Zhao, W., Kita, Y., Iannascoli, B., Khun, H., van Rooijen, N., Shimizu, T., Schwartz, L. B., Daëron, M., et al. (2011) · Blood · doi:10.1182/blood-2011-07-367334 · Cited by 150
Taking immunogenicity assessment of therapeutic proteins to the next level
Büttel, I., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P. M., Lubiniecki, A. S., et al. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.01.006 · Cited by 145
Lei, S., Lei, H., Green, D., Gill, J. C., Conti‐Fine, B. M., & Reding, M. T. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613257 · Cited by 141
Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies
Fehr, T. H., Bachmann, M. F., Bucher, E. M., Kalinke, U., Padova, F. E. D., Lang, A. B., Hengartner, H., & Zinkernagel, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.10.1785 · Cited by 135
Rojas, J. R., Taylor, R. P., Cunningham, M. R., Rutkoski, T. J., Vennarini, J., Jang, H., Graham, M. A., Geboes, K. J., Rousselle, S. D., & Wagner, C. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079277 · Cited by 130
Korswagen, L.-A., Bartelds, G. M., Krieckaert, C. L. M., Turkstra, F., Nurmohamed, M. T., van Schaardenburg, D., Wijbrandts, C. A., Tak, P. P., Lems, W. F., Dijkmans, B. A. C., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30209 · Cited by 121
CR1 and CR1‐like: the primate immune adherence receptors
Birmingham, D. J., & Hebert, L. A. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800109.x · Cited by 111
Immunogenicity/Hypersensitivity of Biologics
Leach, M. W., Rottman, J. B., Hock, M. B., Finco, D., Rojko, J. L., & Beyer, J. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623313510987 · Cited by 106
(2007) · PubMed · Cited by 100
Immunogenicity of Therapeutic Proteins
Schellekens, H., & Jiskoot, W. (2013) · CRC Press eBooks · doi:10.3109/9781420044386-10 · Cited by 96
Rup, B., Pallardy, M. J., Sikkema, D., Albert, T., Allez, M., Broët, P., Carini, C., Creeke, P. I., Davidson, J. E., de Vries, N., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12652 · Cited by 88
Expression and role of Fc- and complement-receptors on human dendritic cells
Bajtay, Z., Csomor, E., Sándor, N., & Erdei, A. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.023 · Cited by 86
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85
Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies
van Schouwenburg, P. A., Kruithof, S., Votsmeier, C., van Schie, K. A., Hart, M. H. L., de Jong, R. N., van Buren, E. E. L., van Ham, S. M., Aarden, L. A., Wolbink, G., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.615500 · Cited by 75
Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
Vultaggio, A., Maggi, E., & Matucci, A. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283464bcd · Cited by 74
Bendtzen, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00109 · Cited by 73
Immunogenicity of biological therapeutics: from assay to patient
Krieckaert, C. L. M., Rispens, T., & Wolbink, G. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283521c4e · Cited by 73
Drug-induced Immune Thrombocytopenia
Chong, B. H., Choi, P., Khachigian, L. M., et al. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.02.003 · Cited by 70
IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients
van Schouwenburg, P. A., Krieckaert, C. L. M., Nurmohamed, M. T., Hart, M. H. L., Rispens, T., Aarden, L. A., Wouters, D., & Wolbink, G. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9705-0 · Cited by 69
Kim, M.-S., Lee, S., Song, M.-Y., Yoo, T. H., Lee, B.-K., & Kim, Y. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.10.034 · Cited by 66
Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview
Kromminga, A., & Schellekens, H. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1313.027 · Cited by 63
Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A., Pozzilli, C., & Antonelli, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00173-4 · Cited by 61
Managing unwanted immunogenicity of biologicals
Deehan, M. R., Garcês, S., Kramer, D., Baker, M., Rat, D., Roettger, Y., & Kromminga, A. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.02.007 · Cited by 59
Scagnolari, C., Bellomi, F., Turriziani, O., Bagnato, F. R., Tomassini, V., Lavolpe, V., Ruggieri, M., Bruschi, F., Meucci, G., Dicuonzo, G., et al. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/107999002753536176 · Cited by 51
Mechanisms of Adverse Drug Reactions to Biologics
Clarke, J. B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_16 · Cited by 48
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions
Vultaggio, A., Nencini, F., Pratesi, S., Petroni, G., Maggi, E., & Matucci, A. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0139 · Cited by 47
Mueller, R., Karle, A. C., Vogt, A. B., Kropshofer, H., Ross, A., Mäder, K., & Mahler, H. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21672 · Cited by 47
Immune Complex-Mediated Enhancement of Secondary Antibody Responses
Goins, C. L., Chappell, C. P., Shashidharamurthy, R., Selvaraj, P., & Jacob, J. (2010) · Journal of Immunology · doi:10.4049/jimmunol.0902530 · Cited by 46
Associations of genetic polymorphisms of Siglecs with human diseases
Angata, T. (2014) · Glycobiology · doi:10.1093/glycob/cwu043 · Cited by 42
Immunogenicity of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse315 · Cited by 38
Induced Expression of FcγRIIIa (CD16a) on CD4+ T Cells Triggers Generation of IFN-γhigh Subset
Chauhan, A., Chen, C., Moore, T. L., & DiPaolo, R. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599266 · Cited by 36
Kloks, C. P. A. M., Berger, C., Cortez, P., Dean, Y. D., Heinrich, J. N., Jensen, L. B., Koppenburg, V., Kostense, S., Kramer, D., Spindeldreher, S., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.01.003 · Cited by 36
Drug-induced immune thrombocytopenia.
Cathomas, R., Goldhirsch, A., & von Moos, R. (2007) · PubMed · Cited by 34
Bendtzen, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00152 · Cited by 32
Antibodies against interferon-beta in multiple sclerosis
Aarskog, N. K., Marøy, T. H., Myhr, K., & Vedeler, C. A. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.04.012 · Cited by 29
Chauhan, A., & Moore, T. L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04505.x · Cited by 24
Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples
Pierog, P., Krishna, M., Yamniuk, A. P., Chauhan, A., & Desilva, B. S. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.11.007 · Cited by 20
Self-citationHoeyveld, E. V., & Bossuyt, X. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.2.283 · Cited by 14
Sethu, S., Govindappa, K., Quinn, P., Wadhwa, M., Stebbings, R., Boggild, M., Naisbitt, D. J., Kimber, I., Pirmohamed, M., Park, K., et al. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.05.008 · Cited by 12
Antidrug Antibodies: B Cell Immunity Against Therapy
Fogdell‐Hahn, A. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12327 · Cited by 11
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Rational Design of Immunomodulatory Hydrogels for Chronic Wound Healing
Kharaziha, M., Baidya, A., & Annabi, N. (2021) · Advanced Materials · doi:10.1002/adma.202100176 · Cited by 721
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“The constant domains, in particular, are highly immunogenic across species barriers (26, 34, 35).”
BackgroundLocalized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
Machine learning for functional protein design
Notin, P., Rollins, N., Gal, Y., Sander, C., & Marks, D. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02127-0 · Cited by 270
Metadata
- Authors
- Krishna, M., & Nadler, S. G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2016-02-02
- Volume
- 7
- Pages
- 21-21
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2290515360
- Cited by
- 389
- References
- 85
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.